Renin-angiotensin system (ACEIs and/or ARBs) (versus unexposed) updated on 03-11-2025

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17143
R71881		 Bane - ACEs/ARB (Controls unexposed sick), 2024 Superimposed preeclampsia in pregnancy during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 1.42 [0.83;2.43] C 79/740   18/232 97 740
ref
S17123
R71690		 Van der Zande - ACE-Is and/or ARBs, 2024 Pre-eclampsia and HELLP syndrome during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) Renin angiotensin: ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) 3.76 [1.33;10.68] C 4/42   155/5,697 159 42
ref
Total 2 studies 2.08 [0.82;5.27] 256 782
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bane - ACEs/ARB (Controls unexposed sick), 2024Bane - ACEs/ARB, 2024 1 1.42[0.83; 2.43]9774061%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Van der Zande - ACE-Is and/or ARBs, 2024Van der Zande - ACE-Is and/or ARBs, 2024 3.76[1.33; 10.68]1594239%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 62% 2.08[0.82; 5.27]2567820.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.08[0.82; 5.27]25678262%NABane - ACEs/ARB (Controls unexposed sick), 2024 Van der Zande - ACE-Is and/or ARBs, 2024 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 2.08[0.82; 5.27]25678262%NABane - ACEs/ARB (Controls unexposed sick), 2024 Van der Zande - ACE-Is and/or ARBs, 2024 2 Tags Adjustment   - No  - No 2.08[0.82; 5.27]25678262%NABane - ACEs/ARB (Controls unexposed sick), 2024 Van der Zande - ACE-Is and/or ARBs, 2024 2 Indications Antihypertensive   - Only cardiac indications other than ...  - Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 3.76[1.33; 10.68]15942 -NAVan der Zande - ACE-Is and/or ARBs, 2024 1   - Only chronic hypertension indication  - Only chronic hypertension indication 1.42[0.83; 2.43]97740 -NABane - ACEs/ARB (Controls unexposed sick), 2024 1 Renin angiotensin   - ARBs and/or ACEIs (Angiotensin II r ...  - ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) 3.76[1.33; 10.68]15942 -NAVan der Zande - ACE-Is and/or ARBs, 2024 1 All studiesAll studies 2.08[0.82; 5.27]25678262%NABane - ACEs/ARB (Controls unexposed sick), 2024 Van der Zande - ACE-Is and/or ARBs, 2024 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 2.08[0.82; 5.27]25678262%NABane - ACEs/ARB (Controls unexposed sick), 2024 Van der Zande - ACE-Is and/or ARBs, 2024 20.510.01.0